Thomas Mark

748 total citations
20 papers, 391 citations indexed

About

Thomas Mark is a scholar working on Genetics, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Thomas Mark has authored 20 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in Thomas Mark's work include Genetic and phenotypic traits in livestock (8 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (7 papers). Thomas Mark is often cited by papers focused on Genetic and phenotypic traits in livestock (8 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (7 papers). Thomas Mark collaborates with scholars based in Denmark, United States and Canada. Thomas Mark's co-authors include Haja N. Kadarmideen, Duy Ngoc, Anders Bjerring Strathe, Just Jensen, Tage Ostersen, Mansoor Husain, Ildiko Lingvay, Anders G. Holst, Lisette J. A. Kogelman and Merete Fredholm and has published in prestigious journals such as PLoS ONE, Diabetes and Diabetes Obesity and Metabolism.

In The Last Decade

Thomas Mark

20 papers receiving 375 citations

Peers

Countries citing papers authored by Thomas Mark

Since Specialization

Citations

This map shows the geographic impact of Thomas Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Mark more than expected).

Fields of papers citing papers by Thomas Mark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Mark. The network helps show where Thomas Mark may publish in the future.

Co-authorship network of co-authors of Thomas Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Mark. A scholar is included among the top collaborators of Thomas Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Mark. Thomas Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1 2023 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Andrew Blauvelt, Jonathan I. Silverberg, Michael J. Cork, Norito Katoh, Thomas Mark, (unknown), Andreas Wollenberg	7
2	Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis 2023 ·JAMA Dermatology ·Joseph F. Merola, Daniel Butler, Thomas Mark, (unknown), (unknown), Katrina Abuabara	13
3	Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis 2022 ·SKIN The Journal of Cutaneous Medicine ·(unknown), April W. Armstrong, Leon Kircik, Jonathan I. Silverberg, Andrew Blauvelt, (unknown), (unknown), Thomas Mark, Melinda Gooderham, Andrew Alexis	1
4	Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2 2021 ·SKIN The Journal of Cutaneous Medicine ·Eric L. Simpson, (unknown), Weily Soong, Thomas Mark, Alexandra Kuznetsova, Louise Abildgaard Steffensen, Jonathan I. Silverberg	1
5	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials 2020 ·Cardiovascular Diabetology ·Mansoor Husain, Stephen C. Bain, Anders G. Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay	34
6	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) 2020 ·Diabetes and Vascular Disease Research ·Aslam Amod, John B. Buse, Darren K. McGuire, Thomas R. Pieber, Rodica Pop‐Busui, Richard E. Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark, Neil R Poulter, (unknown)	4
7	Glomerular Filtration Rate and Associated Risks ofCardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes:Secondary Analysis (DEVOTE 11) 2019 ·Diabetes Therapy ·Aslam Amod, John B. Buse, Darren K. McGuire, Thomas R. Pieber, Rodica Pop‐Busui, Richard E. Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark, Neil R Poulter, (unknown)	15
8	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14 2019 ·Cardiovascular Diabetology ·Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R. Pieber, Thomas Mark, (unknown), Daniél Vega Møller, Bernard Zinman, (unknown)	14
9	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) 2019 ·Diabetes Obesity and Metabolism ·Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Bernard Zinman, Charlotte T. Hansen, M. Hansen, Thomas Mark, Alan C. Moses, John B. Buse, (unknown)	12
10	Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (=65 Years) with Type 2 Diabetes (T2D)—Observations from DEVOTE 2018 ·Diabetes ·Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Neil R Poulter, Charlotte T. Hansen, M. Hansen, Thomas Mark, Alan C. Moses, Bernard Zinman, (unknown)	1
11	Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)-DEVOTE Results 2018 ·Diabetes ·Aslam Amod, Scott S. Emerson, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Rodica Pop‐Busui, Richard E. Pratley, Bernard Zinman, M. Hansen, Ting Jia, Thomas Mark, Neil R Poulter, (unknown)	3
12	Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals 2017 ·PLoS ONE ·S. Frederiksen, Peter Karlskov‐Mortensen, Sameer D. Pant, Maryse Guérin, Philippe Lesnik, Claus B. Jørgensen, Susanna Cirera, (unknown), Thomas Mark, Merete Fredholm	5
13	Genomic applications in horse breeding 2016 ·Animal Frontiers ·K.F. Stock, Lina Jönsson, Anne Ricard, Thomas Mark	15
14	Comparative Analyses of QTLs Influencing Obesity and Metabolic Phenotypes in Pigs and Humans 2015 ·PLoS ONE ·Sameer D. Pant, Peter Karlskov‐Mortensen, (unknown), Susanna Cirera, Lisette J. A. Kogelman, (unknown), Thomas Mark, Claus B. Jørgensen, Niels Grarup, Emil V. R. Appel, (unknown), Torben Hansen, Oluf Pedersen, Maryse Guérin, Thierry Huby, (unknown), T.H.E. Meuwissen, Haja N. Kadarmideen, Merete Fredholm	34
15	Genome-wide association and systems genetic analyses of residual feed intake, daily feed consumption, backfat and weight gain in pigs 2014 ·BMC Genetics ·Duy Ngoc, Tage Ostersen, Anders Bjerring Strathe, Thomas Mark, Just Jensen, Haja N. Kadarmideen	90
16	Genetic Correlations between Young Horse and Dressage Competition Results in Danish Warmblood Horses 2014 ·Research at the University of Copenhagen (University of Copenhagen) ·Lina Jönsson, (unknown), (unknown), Thomas Mark	2
17	Genome-Wide Association Study Reveals Genetic Architecture of Eating Behavior in Pigs and Its Implications for Humans Obesity by Comparative Mapping 2013 ·PLoS ONE ·Duy Ngoc, Anders Bjerring Strathe, Tage Ostersen, Just Jensen, Thomas Mark, Haja N. Kadarmideen	72
18	An F2 Pig Resource Population as a Model for Genetic Studies of Obesity and Obesity-Related Diseases in Humans: Design and Genetic Parameters 2013 ·Frontiers in Genetics ·Lisette J. A. Kogelman, Haja N. Kadarmideen, Thomas Mark, Peter Karlskov‐Mortensen, (unknown), Susanna Cirera, (unknown), Claus B. Jørgensen, Merete Fredholm	34
19	Estimation of (co)variances for genomic regions of flexible sizes: application to complex infectious udder diseases in dairy cattle 2012 ·Genetics Selection Evolution ·Lars Peter Sørensen, Luc Janss, Per Madsen, Thomas Mark, Mogens Sandø Lund	10
20	What Every Pianist Needs to Know About the Body 2004 ·Thomas Mark, (unknown), (unknown)	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact